(919) 237-4897 info@t3dtherapeutics.com

T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959, an investigational new drug candidate that has the potential to be transformative by slowing, stopping or reversing Alzheimer’s disease.

Read more